United Cannabis Revenue Growth Rates (CNAB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
United Cannabis Corp  (CNAB)
 

CNAB's Revenue Growth by Quarter and Year

United Cannabis's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CNAB Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December -
3rd Quarter September 4.72
2nd Quarter June 3.96
1st Quarter March 4.41
FY 13.09

CNABs Annual Revenue
United Cannabis's Revenue in the fiscal year 2018 $ 7.24 millions
United Cannabis's Revenue in the fiscal year 2017 $ 0.36 millions
United Cannabis's Revenue in the fiscal year 2016 $ 0.72 millions
United Cannabis's Revenue in the fiscal year 2015 $ 0.56 millions
United Cannabis's Revenue in the fiscal year 2014 $ 0.19 millions




CNAB Revenue third quarter 2019 Y/Y Growth Comment
United Cannabis Corp reported Revenue surge of 121.79% year on year in the third quarter 2019, to $ 4.72 millions, this is lower than United Cannabis Corp's recent average Revenue surge of 351.9%.

Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Revenue growth. While United Cannabis Corp' s Revenue doubling of 121.79% ranks overall at the positon no. 235 in the third quarter 2019.


CNAB Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December - - - -66.67 %
3rd Quarter September 121.79 % 2030 % -61.54 % 100 %
2nd Quarter June 112.9 % 1062.5 % -20 % -35.48 %
1st Quarter March 1533.33 % 42.11 % -24 % 177.78 %
FY   - 1911.11 % -50 % -

Financial Statements
United Cannabis's third quarter 2019 Revenue $ 4.72 millions CNAB's Income Statement
United Cannabis's third quarter 2018 Revenue $ 2.13 millions Quarterly CNAB's Income Statement


CNAB Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - 39.91 % - -96.15 %
3rd Quarter September 19.3 % 14.52 % -37.5 % 30 %
2nd Quarter June -10.2 % 588.89 % -15.79 % -20 %
1st Quarter March 47.99 % - 1800 % 733.33 %
FY (Year on Year)   - 1911.11 % -50 % -


Back to CNAB Growth rate Comparisons >> Back to CNAB Growth rate Comparisons >>


Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #74
Overall #235

Revenue Y/Y Growth Statistics
High Average Low
1977.05 % 351.9 % -100 %
(Sep 30 2018)   (Dec 31 2015)
Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #74
Overall #235
Revenue Y/Y Growth Statistics
High Average Low
1977.05 % 351.9 % -100 %
(Sep 30 2018)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

United Cannabis's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
599.21 % 51.17 % -100 %
(Jun 30 2018)  


CNAB's III. Quarter Q/Q Revenue Comment
United Cannabis Corp achieved in the III. Quarter 2019 below company average Revenue jump of 19.3% quarter on quarter, to $ 4.72 millions.

Although the III. Quarter 2019 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 14.52% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While United Cannabis's Revenue growth quarter on quarter, overall rank is 544.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #132
Overall #544
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #132
Overall #544
Revenue Q/Q Growth Statistics
High Average Low
599.21 % 51.17 % -100 %
(Jun 30 2018)  


CNAB's III. Quarter Q/Q Revenue Comment
United Cannabis Corp achieved in the III. Quarter 2019 below company average Revenue jump of 19.3% quarter on quarter, to $ 4.72 millions.

III. Quarter 2019 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 14.52% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue quarter on quarter growth. While United Cannabis's Revenue growth quarter on quarter, overall rank is 544.


United Cannabis's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)
Cumulative Revenue 12 Months Ending $ 16.08 $ 13.49 $ 11.39 $ 7.24 $ 4.17
Y / Y Revenue Growth (TTM) 286.01 % 531.39 % 2495.16 % 1899.49 % 798.15 %
Year on Year Revenue Growth Overall Ranking # 84 # 29 # 15 # 149 # 3597
Seqeuential Revenue Change (TTM) 19.21 % 18.43 % 57.23 % 73.89 % 94.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 243 # 236 # 62 # 11 # 3034


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, United Cannabis's cumulative twelve months Revenue were $ 16 millions, company would post below average annual Revenue growth of 94.99% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the United Cannabis's Revenue growth from the 3.96% growth in Jun 30 2019.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 29 to 84.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 24
Overall # 84

Revenue TTM Y/Y Growth Statistics
High Average Low
2495.16 %
 828.61 %
-51.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 70
S&P 500 # 243
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, United Cannabis's cumulative twelve months Revenue were $ 16 millions, company would post below average annual Revenue growth of -51.09% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the United Cannabis's Revenue growth from the 3.96% growth in Jun 30 2019.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 29 to 84.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 24
Overall # 84

Revenue TTM Y/Y Growth Statistics
High Average Low
2495.16 %
828.61 %
-51.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 70
S&P 500 # 243




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CNAB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2019
Flexion Therapeutics Inc 211.67%$ 211.674 millions
Tetraphase Pharmaceuticals Inc190.18%$ 190.182 millions
Palatin Technologies Inc 182.22%$ 182.217 millions
Guardant Health Inc 180.51%$ 180.509 millions
Regenxbio Inc 177.04%$ 177.045 millions
Zyla Life Sciences174.57%$ 174.574 millions
Scienture Holdings Inc 172.74%$ 172.744 millions
Portola Pharmaceuticals inc 159.57%$ 159.568 millions
Aerie Pharmaceuticals Inc 153.96%$ 153.958 millions
Endonovo Therapeutics Inc 153.63%$ 153.633 millions
Vbi Vaccines Inc149.81%$ 149.807 millions
Invo Fertility Inc 142.88%$ 142.880 millions
Ibio inc 140.00%$ 140.000 millions
Corbus Pharmaceuticals Holdings Inc 137.40%$ 137.404 millions
Titan Medical Inc137.13%$ 137.127 millions
Lite Strategy Inc 137.09%$ 137.090 millions
Amicus Therapeutics inc 136.78%$ 136.784 millions
Fate Therapeutics Inc 136.74%$ 136.745 millions
Chemocentryx Inc.135.79%$ 135.788 millions
Biocardia Inc 130.95%$ 130.952 millions
Igc Pharma Inc 124.54%$ 124.538 millions
United Cannabis Corp121.55%$ 121.551 millions
Cardiff Lexington Corporation120.75%$ 120.754 millions
Progyny Inc 120.15%$ 120.145 millions
Ultragenyx Pharmaceutical Inc 119.33%$ 119.332 millions
Cue Biopharma Inc 119.15%$ 119.154 millions
Healthlynked Corp117.29%$ 117.292 millions
Heron Therapeutics Inc 115.43%$ 115.425 millions
Biodelivery Sciences International Inc 114.09%$ 114.086 millions
Spark Therapeutics Inc 109.65%$ 109.648 millions


About United Cannabis Revenue Growth Rates (CNAB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.